| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1525-0016(03)00199-0 |
| P698 | PubMed publication ID | 12946314 |
| P50 | author | Ta-Chiang Liu | Q57179230 |
| Richard Hill | Q39965266 | ||
| P2093 | author name string | Yaohe Wang | |
| David Kirn | |||
| Jennelle Francis | |||
| Gunnel Halldén | |||
| Nick R Lemoine | |||
| Arthi Anand | |||
| Lynda Hawkins | |||
| P2860 | cites work | Modeling and analysis of a virus that replicates selectively in tumor cells | Q45736176 |
| Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity | Q45751042 | ||
| A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy | Q45888206 | ||
| ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents | Q46343726 | ||
| A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. | Q52537791 | ||
| An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy | Q64380394 | ||
| HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses | Q24312224 | ||
| Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect--a histopathological and immunohistochemical study | Q24801703 | ||
| Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein | Q33807026 | ||
| Role of early region 3 (E3) in pathogenesis of adenovirus disease | Q33858906 | ||
| Conditionally replicating herpes vectors for cancer therapy | Q33882697 | ||
| Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer | Q33904270 | ||
| a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 | ||
| Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? | Q34225918 | ||
| Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer | Q34293607 | ||
| Replication-selective virotherapy for cancer: Biological principles, risk management and future directions | Q34297058 | ||
| Adenovirus RIDbeta subunit contains a tyrosine residue that is critical for RID-mediated receptor internalization and inhibition of Fas- and TRAIL-induced apoptosis | Q34356569 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| The role of adenovirus E4orf4 protein in viral replication and cell killing | Q34468774 | ||
| Reovirus therapy of tumors with activated Ras pathway | Q34479740 | ||
| The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid | Q35865485 | ||
| Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes | Q35880562 | ||
| Antineoplasic activity of parvoviruses | Q36935786 | ||
| Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. | Q37269915 | ||
| A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia | Q37412249 | ||
| Productive replication of human adenoviruses in mouse epidermal cells | Q39589975 | ||
| Infection of Mouse Liver by Human Adenovirus Type 5 | Q40171854 | ||
| Adenovirus proteins that subvert host defenses | Q40397955 | ||
| Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy | Q40770884 | ||
| The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants | Q41196115 | ||
| Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects | Q41710263 | ||
| Molecular biology of adenovirus type 2 semipermissive infections. I. Viral growth and expression of viral replicative functions during restricted adenovirus infection | Q42812969 | ||
| Restricted replication of adenovirus type 2 in mouse Balb/3T3 cells | Q42813047 | ||
| P433 | issue | 3 | |
| P921 | main subject | Adenoviridae | Q193447 |
| oncolytic virus | Q1560099 | ||
| P304 | page(s) | 412-424 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy | |
| P478 | volume | 8 |
| Q39241643 | A mouse mammary epithelial cell line permissive for highly efficient human adenovirus growth |
| Q34983995 | A novel immunocompetent murine model for replicating oncolytic adenoviral therapy |
| Q39342575 | A novel immunocompetent murine tumor model for the evaluation of RCAd-enhanced RDAd transduction efficacy |
| Q33586974 | A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology |
| Q47547236 | Adenovirus Lacking E1b Efficiently Induces Cytopathic Effect in HPV-16-Positive Murine Cancer Cells via Virus Replication and Apoptosis. |
| Q40546345 | An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency |
| Q64905542 | An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate In Vivo. |
| Q39491356 | An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. |
| Q39955401 | An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors |
| Q38470166 | Arming oncolytic viruses to leverage antitumor immunity |
| Q45401411 | Biodistribution and tumor infectivity of semliki forest virus vectors in mice: effects of re-administration. |
| Q37209263 | CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells |
| Q36723147 | Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer |
| Q34293923 | Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models |
| Q40440806 | Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer |
| Q40203638 | Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer |
| Q39881872 | Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters |
| Q33610214 | Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model |
| Q40045957 | E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models |
| Q40626795 | E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models |
| Q33486534 | Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression |
| Q40327515 | Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses |
| Q54959132 | Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus. |
| Q55395331 | Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells. |
| Q51847569 | Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy. |
| Q40416354 | Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. |
| Q36072604 | Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development |
| Q38808882 | HAdV-2-suppressed growth of SV40 T antigen-transformed mouse mammary epithelial cell-induced tumours in SCID mice |
| Q53809292 | Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature. |
| Q36209205 | INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. |
| Q36184357 | Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus |
| Q39752863 | Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers |
| Q40350503 | Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells |
| Q38702903 | Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. |
| Q60911893 | Microbubble-mediated delivery of human adenoviruses does not elicit innate and adaptive immunity response in an immunocompetent mouse model of prostate cancer |
| Q37145300 | Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors |
| Q39135464 | Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs |
| Q26777406 | Oncolytic Replication of E1b-Deleted Adenoviruses |
| Q37448942 | Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time |
| Q35811062 | Oncolytic adenovirus targeting cyclin E overexpression repressed tumor growth in syngeneic immunocompetent mice |
| Q27004796 | Oncolytic adenovirus-mediated therapy for prostate cancer |
| Q36318189 | Oncolytic adenoviruses - selective retargeting to tumor cells |
| Q36099082 | Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q35864258 | Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity. |
| Q39753154 | Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming. |
| Q40478143 | Productive replication of human adenovirus type 5 in canine cells. |
| Q36088950 | Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963 |
| Q34545667 | Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species |
| Q42370561 | Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy |
| Q34343742 | Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity |
| Q34556808 | Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. |
| Q36488714 | Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4 |
| Q37185367 | The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors |
| Q99576115 | Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer |
| Q96817230 | Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic |
| Q35572421 | Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice |
| Q36254857 | Viruses with deletions in antiapoptotic genes as potential oncolytic agents. |
| Q37502453 | Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model. |
Search more.